Official Title
Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2
Brief Summary

The study objectives were to assess 1/the immune status of healthcare professionals with suggestive symptomatology of Covid-19 infection and 2/the sensitivity and specificity of AAZ rapid test by comparing it with a serological ELISA test. An open-label, monocentric, prospective, non-randomized study, is conducted, including 50 hospital healthcare professionals and 50 private health professionals. Knowledge of serostatus will achieve the implementation of a strategy of management of patients according to specific immunity of health professionals

Status
Completed
Conditions
Covid-19 Immune Status of Healthcare Workers
Interventions

Diagnostic Test: AAZ Covid-19 rapid test

To assess the immune status
Other Name: ELISA test

Eligibility Criteria

Inclusion Criteria:

- Healthcare professionals with symptoms suggestive of Covid-19 infection

Exclusion Criteria:

- any other subject

- pregnant women

- protected adult

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Bichat University Hospital
Paris, France

Investigators

Elisabeth Bouvet, MD, Principal Investigator
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux

Sponsors / Collaborators
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
NCT Number
NCT04525417
MeSH Terms
COVID-19